Strokes can be either ischemic or hemorrhagic. In an ischemic stroke, the blood supply to part of the brain is cut off because atherosclerosis or a blood clot has blocked a blood vessel.
Location: Spain, Catalonia, Barcelona
Employees: 11-50
Total raised: $40.49M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Sabadell V... | sabadellve... |
| - | Omega Fund... | omegafunds... |
| - | Asabys Par... | asabys.com... |
| - | Ysios Capi... | ysioscapit... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.12.2019 | - | $23.64M | - |
| 23.05.2017 | Series A | $16.86M | Omega Fund... |
Mentions in press and media 8
| Date | Title | Description |
| 04.12.2019 | Anaconda Biomed Raises €20M Funding Round | Anaconda Biomed S.L., a Barcelona, Spain-based medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, closed €20m in new funding. The round was led by Asabys Partners from its fund, ... |
| 06.11.2019 | Anaconda biomed, owned by Ysios, announces first-in-human study of Next-generation thrombectomy system | 06/11/2019 Nota de prensa ANACONDA BIOMED, OWNED BY YSIOS, ANNOUNCES FIRST-IN-HUMAN STUDY OF NEXT-GENERATION THROMBECTOMY SYSTEM. Trial Data to Support Regulatory Submission to U.S. Food and Drug Administration • Ysios Capital led the 1... |
| 23.05.2017 | Anaconda Biomed receives €15 million in financing | Anaconda Biomed, a pre-clinical stage medical device company, closed a €15 million Series A financing. It was backed by new investors including Ysios Capital, Banco Sabadell, and Omega Funds, in addition to current investor Innogest Capital... |
| 23.05.2017 | Anaconda Biomed Closes €15M Series A Financing | Anaconda Biomed, a Barcelona, Spain-based pre-clinical stage medical device company focused on the development of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), closed a €15m Series A financing. Backers include... |
| 23.05.2017 | Anaconda Biomed cierra una ronda de €15M liderada por Ysios, acude Banco Sabadell | 23/05/2017 Nota de prensa ANACONDA BIOMED CIERRA UNA RONDA DE €15 MILLONES LIDERADA POR YSIOS CAPITAL, ACUDE BANCO SABADELL. Anaconda Biomed, compañía especializada en el desarrollo de catéteres de nueva generación para mejorar la seguri... |
| 23.05.2017 | Term Sheet — Tuesday, May 23 | FALSE START Good morning – today’s column didn’t come together in time. Back tomorrow! • Can China Save Hollywood? Paid Content What you need to know about growing cyberattacks From ExtraHop • The Fortune 100 Companies Doing the Most to Sto... |
| 22.05.2017 | Anaconda Biomed Secures 15M Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds | Anaconda Biomed, a pre-clinical stage medical device company focused on the development of the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announces it has closed a Series A financin... |
| - | ANACONDA BIOMED S.L. secures €20 Million round of funding | Proceeds to Be Used for Clinical Studies, Regulatory Submissions, Further Product Development and Manufacturing Scale-up Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment o... |